Seeking Alpha

Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw

Innovative GFAP blood biomarker test expands Labcorp's (LH) portfolio of tests for diseases including Alzheimer's disease, multiple sclerosis, glioblastoma and brain injuries BURLINGTON, N.C., April ...
Seeking Alpha

Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease

BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ -- Labcorp, a global leader of innovative and comprehensive laboratory services, announced today the availability of the Lumipulse® pTau-217/Beta Amyloid ...
FierceBiotech

Labcorp launches blood test for a wide range of neurodegenerative diseases and brain injuries

The clinical services giant Labcorp is rolling out its first blood test to help identify and confirm the signs of multiple neurodegenerative diseases and brain injury, including ALS, dementia and ...
Nasdaq

Labcorp Debuts First FDA-Cleared Blood Test for Alzheimer's, Stock Up

Labcorp Holdings, Inc. LH has announced the nationwide availability of the Lumipulse pTau-217/Beta Amyloid 42 Ratio — the first FDA-cleared blood-based in-vitro diagnostic (IVD) test to assist in ...
Morningstar

Labcorp to Offer First FDA-Cleared Blood Test to Rule out Alzheimer's-Related Amyloid Pathology in Primary Care Settings

BURLINGTON, N.C., Oct. 23, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys pTau181 test, the ...
Morningstar

Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease

Lumipulse® pTau-217/Beta Amyloid 42 Ratio now available nationwide through Labcorp BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive ...